Samuel E. DePrimo
Poseida Therapeutics (United States)(US)
Publications by Year
Research Areas
Gastrointestinal Tumor Research and Treatment, Renal cell carcinoma treatment, Colorectal Cancer Treatments and Studies, Chronic Myeloid Leukemia Treatments, Psoriasis: Treatment and Pathogenesis
Most-Cited Works
- → Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma(2005)1,630 cited
- → Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer(2005)1,150 cited
- → Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane(2008)483 cited
- → Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma(2008)392 cited
- → Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure(2009)366 cited
- → Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins(2007)320 cited
- → Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study(2009)288 cited
- → Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers(2010)250 cited
- → Mechanisms of G2 Arrest in Response to Overexpression of p53(1999)194 cited
- → Transcriptional programs activated by exposure of human prostate cancer cells to androgen(2002)193 cited